참고문헌
- Abbasi MM, Jahanban-Esfahlan R, Monfaredan A, et al (2014). Oral and IV dosages of doxorubicin-methotrexate loadednanoparticles inhibit progression of oral cancer by downregulation of matrix methaloproteinase 2 expression in vivo. Asian Pac J Cancer Prev, 15, 10705-11.
- Bedal KB, Grassel S, Oefner PJ, et al (2014). Collagen XVI induces expression of MMP9 via modulation of AP-1 transcription factors and facilitates invasion of oral squamous cell carcinoma. PLoS ONE, 9, 86777. https://doi.org/10.1371/journal.pone.0086777
- Di Domenico M, Ricciardi C, Fusco A, Pierantoni GM (2011). Anti-VEGF therapy in breast and lung mouse models of cancers. J Biomed Biotechnol, 2011, 947928.
- de Vicente JC, Fresno MF, Villalain L, et al (2005). Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol, 41, 283-93. https://doi.org/10.1016/j.oraloncology.2004.08.013
-
Elahi M, Rakhshan V, Ghasemian NT, Moshref M (2012). Prognostic value of transforming growth factor beta 1 [TGF-
${\beta}1$ ] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers, 17, 21-7. https://doi.org/10.3109/1354750X.2011.635804 - Erdem NF, Carlson ER, Gerard DA, Ichiki AT (2007). Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg, 65, 1725-33. https://doi.org/10.1016/j.joms.2006.11.034
- Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004). Matrix metalloproteinases in cancer: from new functions to improved inhabitation strategies. Int J Dev Biol, 48, 411-24. https://doi.org/10.1387/ijdb.041811af
- Forsyth PA, Wong H, Laing TD, et al (1999). Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer, 79, 1828-35. https://doi.org/10.1038/sj.bjc.6990291
- Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M (2008). Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One, 3, 1774. https://doi.org/10.1371/journal.pone.0001774
- Hong Q, Jun T, Lei J, Xiling J, Tamamura R (2006). Expression and clinical significance of matrix metalloproteinase-2 and its inhibitor TIMP-2 in oral squamous cell carcinoma. J Hard Tissue Biol, 15, 54-60. https://doi.org/10.2485/jhtb.15.54
- Johnson NW, Jayasekara P, Amarasinghe AA (2011). Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontology, 57, 19-37. https://doi.org/10.1111/j.1600-0757.2011.00401.x
- Katayama A, Bandoh N, Kishibe K, et al (2004). Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res, 10, 634-40. https://doi.org/10.1158/1078-0432.CCR-0864-02
- Knapinska A, Fields GB (2012). Chemical biology for understanding matrix metalloproteinase function. Chembiochem, 13, 2002-20. https://doi.org/10.1002/cbic.201200298
- Kondakova IV, Klisho EV, savenkova OV (2008). Matrix metalloproteinase 2 and 9 as the factor of head and neck tumor metastasis. Biomed Khim, 54, 555-60.
- Li M, Wang Z, Xing Y, et al (2014). A Multicenter study on expressions of vascular endothelial growth factor, matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-2 in oral and maxillofacial squamous cell carcinoma. Iran Red Crescent Med J, 16, 13185.
- Liu G, Li J, Li Z, Chen X (2001). The effects of MMPs and TIMPs on the metastasis of oral squamous cell carcinoma to neck lymph nodes. Hua Xi Kou Qiang Yi Xue Za Zhi, 19, 216-8, 224 (in Chinese).
- Makinen LK, Hayry V, Atula T, et al (2012). Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. J Oral Pathol Med, 41, 394-9. https://doi.org/10.1111/j.1600-0714.2011.01110.x
- Mardani M, Andisheh-Tadbir A, Khademi B, Biparva P, Malekzadeh M (2014). Serum level of matrix metalloproteinase-9 in patients with salivary gland tumor. J Dent Shiraz Univ Med Sci, 15, 199-203.
- Mohtasham N, Babakoohi S, Shiva A, et al (2013). Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Pract, 209, 110-4. https://doi.org/10.1016/j.prp.2012.11.002
- Monteiro-Amado F, Castro-Silva II, Lima CJ, et al (2013). Immunohistochemical evaluation of MMP-2, MMP-9 and CD31/microvascular density in squamous cell carcinomas of the floor of the mouth. Braz Dent J, 24, 3-9. https://doi.org/10.1590/0103-6440201301941
- Nikkola J, Vihinen P, Vuoristo MS, et al (2005). High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res, 11, 5158-66. https://doi.org/10.1158/1078-0432.CCR-04-2478
- Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE (2012). Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent, 4, 297-301.
- Rosenthal EL, Matrisian LM (2006). Matrix metalloproteinases in head and neck cancers. Head Neck, 10, 639-48.
- SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A (2008). Salivary concentration of INF6, TNFa, IL1a, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal, 13, 292-5.
- Singh RD, Haridas N, Patel JB, et al (2010). Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem, 25, 250-9. https://doi.org/10.1007/s12291-010-0060-8
- Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG (2012). Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol, 181, 1895-9. https://doi.org/10.1016/j.ajpath.2012.08.044
- Tadbir AA, Purshahidi S, Ebrahimi H (2012). Serum level of MMP-3 in patients with oral squamous cell carcinoma-lack association with clinico-pathological features. Asian Pac J Cancer Prev, 13, 4545-8. https://doi.org/10.7314/APJCP.2012.13.9.4545
- Vilen ST, Salo T, Sorsa T, Nyberg P (2013). Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. Scientific World Journal, 2013, 920595.
- Wang G, Wang W, Zhou J, Yang X (2013). Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer. Cancer Biomark, 13, 21-8. https://doi.org/10.3233/CBM-130332
- Wu ZS, Wu Q, Yang JH, et al (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer, 122, 2050-6. https://doi.org/10.1002/ijc.23337
- Yadav L, Puri N, Rastogi V, et al (2014). Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac J Cancer Prev, 15, 1085-91. https://doi.org/10.7314/APJCP.2014.15.3.1085
- Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000). Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res, 20, 1311-6.
- Zhang J, Yin L, Wu J, et al (2014). Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma. Exp Ther Med, 8, 175-80. https://doi.org/10.3892/etm.2014.1685
피인용 문헌
- A systematic approach to prioritize drug targets using machine learning, a molecular descriptor-based classification model, and high-throughput screening of plant derived molecules: a case study in oral cancer vol.11, pp.12, 2015, https://doi.org/10.1039/C5MB00468C
- Serum Level of Matrix Metalloproteinase-2 and -9 in Patients with Laryngeal Squamous Cell Carcinoma and Clinical Significance vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6749
- Comparison of Serum Fucose Levels in Leukoplakia and Oral Cancer Patients vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7497
- Cigarette smoke extract induces oral squamous cell carcinoma cell invasion in a receptor for advanced glycation end-products-dependent manner vol.126, pp.1, 2018, https://doi.org/10.1111/eos.12395